Poor
Not Aligned
Patient Risk:
High
Summary
Several claims are not supported by the provided FDA label excerpts (notably non-U.S. Australia prescription/supply statements and specific “common side effects” such as dryness/redness/peeling/irritation). The pregnancy claim is directionally consistent with the label’s fetal harm/contraindication theme but may omit required label-specific precautions.
Category Scores
Accurate Statements
Tazarotene is a topical retinoid.
Supported by 11 DESCRIPTION (tazarotene is a retinoid; topical lotion).
Tazarotene is used to treat acne.
Supported by 1 INDICATIONS AND USAGE (topical treatment of acne vulgaris in patients 9 years of age and older).
Tazarotene products can come in different strengths.
Partially supported by 3 DOSAGE FORMS AND STRENGTHS (label excerpt provided for 0.045%). The claim implies multiple strengths, which is not demonstrated in the provided label text.
Tazarotene products can come in different formulations, such as creams or gels.
Not supported by the provided label excerpts. Provided label text shown is for ARAZLO lotion only (0.045% lotion); no creams/gels are demonstrated in the supplied sections.
Unsupported Statements
Tazarotene is used to treat other skin conditions.
Not supported by the provided 1 INDICATIONS AND USAGE excerpt (only acne vulgaris is shown).
In Australia, tazarotene is typically supplied as a prescription medicine.
Geographic regulatory/supply status for Australia is not present in the provided FDA label sections.
Topical retinoids such as tazarotene are commonly prescription-only in Australia.
Geographic regulatory/supply status for Australia is not present in the provided FDA label sections.
Common side effects of tazarotene include dryness.
The provided label excerpts do not list dryness as a common adverse reaction.
Common side effects of tazarotene include redness.
The provided label excerpts do not list redness as a common adverse reaction.
Common side effects of tazarotene include peeling.
The provided label excerpts do not list peeling as a common adverse reaction.
Common side effects of tazarotene include irritation.
The provided label excerpts do not list irritation as a common adverse reaction.
Contradictions
Important Omissions
The pregnancy-related claim does not include the label’s specific pregnancy precaution elements (e.g., ARAZLO is contraindicated in pregnancy; discontinue as soon as pregnancy is recognized; label discusses obtaining a pregnancy test within 2 weeks prior to therapy, initiating therapy during a menstrual period, and using effective contraception during treatment).
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Unsupported adverse-reaction “common side effects” statements and incomplete pregnancy precaution wording could misinform risk management; pregnancy precautions are a high-stakes labeled topic (contraindicated in pregnancy).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Not Aligned
Primary Issue
Multiple claims are unsupported by the supplied FDA label excerpts, including Australia prescription/supply statements and specific “common side effects”; pregnancy precaution wording is incomplete versus label-specific required actions.
Suggested Improvement
Remove or rephrase unsupported Australia regulatory/supply claims; do not assert specific “common side effects” (dryness/redness/peeling/irritation) unless explicitly supported in the provided label adverse reaction section; revise the pregnancy claim to mirror the label’s exact contraindication and required pregnancy precautions (discontinue as soon as pregnancy is recognized; pregnancy test timing; initiation during menstrual period; effective contraception).